These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 17328821

  • 21. Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR.
    Wang Y, Huang Y, Hobbs HH, Cohen JC.
    J Lipid Res; 2012 Sep; 53(9):1932-43. PubMed ID: 22764087
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Self-association of human PCSK9 correlates with its LDLR-degrading activity.
    Fan D, Yancey PG, Qiu S, Ding L, Weeber EJ, Linton MF, Fazio S.
    Biochemistry; 2008 Feb 12; 47(6):1631-9. PubMed ID: 18197702
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD, Lee SE, Yang J, Lee HC, Shin D, Lee H, Lee J, Jin S, Kim S, Lee SJ, You J, Park HW, Nam KY, Lee SH, Park SW, Kim JS, Kim SY, Kwon YW, Kwak SH, Yang HM, Kim HS.
    Eur Heart J; 2020 Jan 07; 41(2):239-252. PubMed ID: 31419281
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.
    Le QT, Blanchet M, Seidah NG, Labonté P.
    J Biol Chem; 2015 Sep 18; 290(38):23385-400. PubMed ID: 26195630
    [Abstract] [Full Text] [Related]

  • 30. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells.
    Levy E, Ben Djoudi Ouadda A, Spahis S, Sane AT, Garofalo C, Grenier É, Emonnot L, Yara S, Couture P, Beaulieu JF, Ménard D, Seidah NG, Elchebly M.
    Atherosclerosis; 2013 Apr 18; 227(2):297-306. PubMed ID: 23422832
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.
    Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML.
    J Biol Chem; 2015 May 01; 290(18):11649-62. PubMed ID: 25778403
    [Abstract] [Full Text] [Related]

  • 33. APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo.
    Fu T, Guan Y, Xu J, Wang Y.
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep 01; 1862(9):883-889. PubMed ID: 28495363
    [Abstract] [Full Text] [Related]

  • 34. Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.
    Kosenko T, Golder M, Leblond G, Weng W, Lagace TA.
    J Biol Chem; 2013 Mar 22; 288(12):8279-8288. PubMed ID: 23400816
    [Abstract] [Full Text] [Related]

  • 35. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.
    Ni YG, Condra JH, Orsatti L, Shen X, Di Marco S, Pandit S, Bottomley MJ, Ruggeri L, Cummings RT, Cubbon RM, Santoro JC, Ehrhardt A, Lewis D, Fisher TS, Ha S, Njimoluh L, Wood DD, Hammond HA, Wisniewski D, Volpari C, Noto A, Lo Surdo P, Hubbard B, Carfí A, Sitlani A.
    J Biol Chem; 2010 Apr 23; 285(17):12882-91. PubMed ID: 20172854
    [Abstract] [Full Text] [Related]

  • 36. MMP-2 inhibits PCSK9-induced degradation of the LDL receptor in Hepa1-c1c7 cells.
    Wang X, Berry E, Hernandez-Anzaldo S, Sun D, Adijiang A, Li L, Zhang D, Fernandez-Patron C.
    FEBS Lett; 2015 Feb 13; 589(4):490-6. PubMed ID: 25613181
    [Abstract] [Full Text] [Related]

  • 37. Role of ubiquitination in PCSK9-mediated low-density lipoprotein receptor degradation.
    Chen Y, Wang H, Yu L, Yu X, Qian YW, Cao G, Wang J.
    Biochem Biophys Res Commun; 2011 Nov 25; 415(3):515-8. PubMed ID: 22074827
    [Abstract] [Full Text] [Related]

  • 38. Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification.
    Tveten K, Holla ØL, Cameron J, Strøm TB, Berge KE, Laerdahl JK, Leren TP.
    Hum Mol Genet; 2012 Mar 15; 21(6):1402-9. PubMed ID: 22156580
    [Abstract] [Full Text] [Related]

  • 39. An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.
    Ly K, Essalmani R, Desjardins R, Seidah NG, Day R.
    J Biol Chem; 2016 Nov 18; 291(47):24676-24687. PubMed ID: 27758865
    [Abstract] [Full Text] [Related]

  • 40. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.
    Strøm TB, Holla ØL, Cameron J, Berge KE, Leren TP.
    Clin Chim Acta; 2010 Feb 18; 411(3-4):229-33. PubMed ID: 19917273
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.